DNMT1 and prostate carcinoma: Treatment with DNMT inhibitors 5-AzaC and 5,6-dihydro-5-azacytidine could restore sensitivity of androgen insensitive human prostate carcinoma cell lines to growth inhibition by anti-androgens (8, 53, 54).